Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7366 to 7380 of 7766 results

  1. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued [GID-TA10863]

  2. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued [GID-TA11004]

  3. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued [GID-TA11020]

  4. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued [GID-TA11244]

  5. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued [GID-TA10958]

  6. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued [GID-TA10583]

  7. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued [GID-TA10525]

  8. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued [GID-TA10185]

  9. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued [GID-TA10502]

  10. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued [GID-TA11255]

  11. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued [GID-TA10929]

  12. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued [GID-TA10848]